These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 22871191

  • 21. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
    Kalgutkar AS, Frederick KS, Hatch HL, Ambler CM, Perry DA, Garigipati RS, Chang GC, Lefker BA, Clark RW, Morehouse LA, Francone O, Hu X.
    Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613
    [Abstract] [Full Text] [Related]

  • 22. Rationale for cholesteryl ester transfer protein inhibition.
    Hewing B, Fisher EA.
    Curr Opin Lipidol; 2012 Aug; 23(4):372-6. PubMed ID: 22517614
    [Abstract] [Full Text] [Related]

  • 23. Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol.
    Wright RS.
    Curr Opin Cardiol; 2013 Jul; 28(4):389-98. PubMed ID: 23736814
    [Abstract] [Full Text] [Related]

  • 24. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
    Chapman MJ, Le Goff W, Guerin M, Kontush A.
    Eur Heart J; 2010 Jan; 31(2):149-64. PubMed ID: 19825813
    [Abstract] [Full Text] [Related]

  • 25. Anacetrapib, a cholesteryl ester transfer protein inhibitor.
    Hooper AJ, Burnett JR.
    Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425
    [Abstract] [Full Text] [Related]

  • 26. Biochemical characterization of cholesteryl ester transfer protein inhibitors.
    Ranalletta M, Bierilo KK, Chen Y, Milot D, Chen Q, Tung E, Houde C, Elowe NH, Garcia-Calvo M, Porter G, Eveland S, Frantz-Wattley B, Kavana M, Addona G, Sinclair P, Sparrow C, O'Neill EA, Koblan KS, Sitlani A, Hubbard B, Fisher TS.
    J Lipid Res; 2010 Sep; 51(9):2739-52. PubMed ID: 20458119
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
    Yamashita S, Ruscica M, Macchi C, Corsini A, Matsuzawa Y, Sirtori CR.
    Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344
    [Abstract] [Full Text] [Related]

  • 29. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
    Sirtori CR.
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1543-54. PubMed ID: 21961529
    [Abstract] [Full Text] [Related]

  • 30. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D.
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [Abstract] [Full Text] [Related]

  • 31. Future of cholesteryl ester transfer protein inhibitors.
    Rader DJ, deGoma EM.
    Annu Rev Med; 2014 Sep; 65():385-403. PubMed ID: 24422575
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Present therapeutic role of cholesteryl ester transfer protein inhibitors.
    Ferri N, Corsini A, Sirtori CR, Ruscica M.
    Pharmacol Res; 2018 Feb; 128():29-41. PubMed ID: 29287689
    [Abstract] [Full Text] [Related]

  • 38. Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.
    Ghosh RK, Ghosh SM.
    Curr Clin Pharmacol; 2012 May; 7(2):102-10. PubMed ID: 22432840
    [Abstract] [Full Text] [Related]

  • 39. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors.
    Miyares MA.
    Ann Pharmacother; 2011 Jan; 45(1):84-94. PubMed ID: 21205945
    [Abstract] [Full Text] [Related]

  • 40. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
    Miyares MA, Davis K.
    Vasc Health Risk Manag; 2012 Jan; 8():483-93. PubMed ID: 22977305
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.